|Day's Range||0.000 - 0.000|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, July 17, 2017-- Ember Therapeutics, Inc., a diversified New York-based pharmaceutical company developing targeted therapies for osteoarthritis, fibrosis, and other regenerative medicines, today ...
NEW YORK, May 01, 2017-- Ember Therapeutics, Inc., a publicly traded company is pleased to announced that it has retained Maxim Group LLC, a leading investment banking securities and investment firm, to ...
Knight Therapeutics Inc. , a leading Canadian specialty pharmaceutical company, and Ember Therapeutics, Inc. , a New York-based biotech company developing targeted therapies for osteoarthritis, kidney ...